BRPI0715544A2 - Anticorpos que modificam doença cancerosas. - Google Patents

Anticorpos que modificam doença cancerosas.

Info

Publication number
BRPI0715544A2
BRPI0715544A2 BRPI0715544-1A2A BRPI0715544A BRPI0715544A2 BR PI0715544 A2 BRPI0715544 A2 BR PI0715544A2 BR PI0715544 A BRPI0715544 A BR PI0715544A BR PI0715544 A2 BRPI0715544 A2 BR PI0715544A2
Authority
BR
Brazil
Prior art keywords
antibodies
cancer diseases
change cancer
change
diseases
Prior art date
Application number
BRPI0715544-1A2A
Other languages
English (en)
Inventor
Susan E Hahn
Luis A G Dacruz
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0715544A2 publication Critical patent/BRPI0715544A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
BRPI0715544-1A2A 2006-07-26 2007-07-24 Anticorpos que modificam doença cancerosas. BRPI0715544A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83343106P 2006-07-26 2006-07-26
PCT/CA2007/001318 WO2008011711A1 (en) 2006-07-26 2007-07-24 Cancerous disease modifying antibodies

Publications (1)

Publication Number Publication Date
BRPI0715544A2 true BRPI0715544A2 (pt) 2014-10-29

Family

ID=38981089

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715544-1A2A BRPI0715544A2 (pt) 2006-07-26 2007-07-24 Anticorpos que modificam doença cancerosas.

Country Status (12)

Country Link
US (1) US20080089891A1 (pt)
EP (1) EP2044119A4 (pt)
JP (1) JP2009545528A (pt)
KR (1) KR20090059106A (pt)
CN (1) CN101547936A (pt)
AU (1) AU2007278792A1 (pt)
BR (1) BRPI0715544A2 (pt)
CA (1) CA2666515A1 (pt)
MX (1) MX2009001015A (pt)
NO (1) NO20090342L (pt)
RU (1) RU2009104624A (pt)
WO (1) WO2008011711A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY171761A (en) 2012-03-14 2019-10-28 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US11191844B2 (en) 2015-07-06 2021-12-07 Regeneran Pharmaceuticals, Inc. Multispecific antigen-binding molecules and uses thereof
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
EP3635009B1 (en) 2017-06-07 2026-02-25 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
IL276464B2 (en) 2018-02-07 2026-01-01 Regeneron Pharma Methods and compositions for administering therapeutic protein
IL278244B2 (en) 2018-04-30 2026-01-01 Regeneron Pharma Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof
MA52626A (fr) 2018-05-17 2021-03-24 Regeneron Pharma Anticorps anti-cd63, conjugués et leurs utilisations
AU2021341888A1 (en) 2020-09-10 2023-05-11 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2 antibodies and methods of use thereof
US20250277052A1 (en) * 2021-03-29 2025-09-04 Immunewalk Therapeutics, Inc. Motile sperm domain containing protein 2, integrin beta2 and cd63
KR102627688B1 (ko) 2021-11-09 2024-01-23 호서대학교 산학협력단 죽단화 꽃 에센셜오일을 유효성분으로 포함하는 피부 재생 및 주름 개선용 화장료 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172124A (en) * 1978-04-28 1979-10-23 The Wistar Institute Method of producing tumor antibodies
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4828991A (en) * 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
NZ222509A (en) * 1986-11-19 1993-03-26 Oncogen Hybridoma cell line producing antibodies binding to tumour-associated mucin antigen
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5296348A (en) * 1989-05-16 1994-03-22 The Wistar Institute Of Anatomy And Biology Methods for screening monoclonal antibodies for therapeutic use
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP0539970B1 (en) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
IL105008A0 (en) * 1992-03-13 1993-07-08 Yeda Res & Dev Double transfectants of mhc genes as cellular vaccines for immunoprevention of tumor metastasis
ATE244888T1 (de) * 1993-02-05 2003-07-15 Epigen Inc Humanes carcinoma-antigen (hca), hca antikörper, hca immunoassays, aufzeichnungsmethoden und therapy
EP0764030B1 (en) * 1994-06-24 2000-09-20 Vladimir P. Torchilin Composition containing autoantibodies for tumor therapy and prophylaxis
US5783186A (en) * 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
WO1999066027A1 (en) * 1998-06-15 1999-12-23 The Research Foundation Of State University Of New York Monoclonal antibodies that recognize antigens associated with tumor metastasis
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US6657048B2 (en) * 1999-10-08 2003-12-02 Arius Research, Inc. Individualized anti-cancer antibodies
US7256271B2 (en) * 2003-01-21 2007-08-14 Arius Research Inc. Cancerous disease modifying antibodies
US20040105816A1 (en) * 1999-10-08 2004-06-03 Young David S. F. Cancerous disease modifying antibodies
US6180357B1 (en) * 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
US20020102638A1 (en) * 2000-01-31 2002-08-01 Rosen Craig A. Nucleic acids, proteins, and antibodies
US7279294B2 (en) * 2000-04-03 2007-10-09 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services, Nih Tumor markers in ovarian cancer
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US20060210474A1 (en) * 2000-11-29 2006-09-21 Young David S Cytotoxicity mediation of cells evidencing surface expression of CD63
US7009040B2 (en) * 2003-01-21 2006-03-07 Arius Research, Inc. Cancerous disease modifying antibodies
US7431923B2 (en) * 2005-01-03 2008-10-07 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
WO2002057303A2 (en) * 2001-01-12 2002-07-25 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
US20040198651A1 (en) * 2001-04-20 2004-10-07 Klammer Aaron A. Secreted proteins
EP2143438B1 (en) * 2001-09-18 2011-07-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors
EP1455819A1 (en) * 2001-12-21 2004-09-15 Arius Research, Inc. Individualized anti-cancer antibodies
US7361342B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cancerous disease modifying antibodies
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP

Also Published As

Publication number Publication date
RU2009104624A (ru) 2010-09-10
CA2666515A1 (en) 2008-01-31
KR20090059106A (ko) 2009-06-10
MX2009001015A (es) 2009-06-22
EP2044119A1 (en) 2009-04-08
AU2007278792A1 (en) 2008-01-31
WO2008011711A1 (en) 2008-01-31
CN101547936A (zh) 2009-09-30
JP2009545528A (ja) 2009-12-24
NO20090342L (no) 2009-04-27
EP2044119A4 (en) 2010-09-01
US20080089891A1 (en) 2008-04-17

Similar Documents

Publication Publication Date Title
HUS2100038I1 (hu) Anti-CD20 antitest készítmények
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
IL197217B (en) Novel anti-cd38 antibodies for the treatment of cancer
BRPI0807991A2 (pt) Anticorpos anti-il-23r elaborados.
CY2016030I2 (el) Αντισωματα εναντι της il-17
PT2115472E (pt) Biomarcadores de cancro
FR2909857B1 (fr) Endovalve.
NO344963B1 (no) Humanisert antistoff
NL1034256A1 (nl) Spectroscopiesysteem.
LT3421498T (lt) Monokloniniai antikūnai prieš klaudiną-18, skirti vėžio gydymui
BRPI0720218A2 (pt) Anticorpos monoclonais contra angptl3
PL3059246T3 (pl) Zmodyfikowany region stały przeciwciała
BRPI0715544A2 (pt) Anticorpos que modificam doença cancerosas.
HRP20150176T1 (xx) Protutijela protiv miostatina
DK1964852T3 (da) Anti-ilt7-antistof
LU92389I2 (fr) Cystéamine
BRPI0817427A2 (pt) Anticorpo anti-bst2
BRPI0807858A2 (pt) Anticorpo de modificação de doença cancerosa
BRPI0819765A2 (pt) Conjugados de anticorpos anti-rg-1
BRPI0807861A2 (pt) Anticorpo de modificação de doença cancerosa
EP2015785A4 (en) AGRM2 ANTIGEN
EP2087103A4 (en) Cancerous disease modifying antibodies
BRPI0718609A2 (pt) Anticorpos modificadores de doença cancerosa.
FR2909834B1 (fr) Andaineuse transversale.
FR2903669B3 (fr) 02isse demontable.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]